Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 meta-analysis

NCT04429711 (Biber), 2020
  NCT04429711		 RCTivermectinplaceboCOVID-19some concern
-/- suggested
  • suggested 1.6-fold increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID 19 hospitalized meta-analysis

Gonzalez (IVER), 2020
  NCT04391127		 RCTivermectinplaceboCOVID 19 hospitalizedsome concern
36/37 inconclusive
    Hashim A, 2020
          NCT04591600    		 RCTivermectinstandard of careCOVID 19 hospitalizedsome concern
    		70/70 inconclusive
    • inconclusive 52 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    I-TECH (Lim), 2022
          NCT04920942    		 RCTivermectincontrolCOVID-19 mild to moderatesome concern
    		241/249 inconclusive
    • inconclusive 25 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
    Kirti, 2021
          CTRI/2020/08/027225    		 RCTivermectinplaceboCOVID-19 mild to moderatesome concern
    		57/58 inconclusive
    • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    Chaccour, 2020
          NCT04390022    		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
    		12/12 inconclusive
    • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
    Krolewiecki, 2020
          NCT004381884    		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
    		30/15 inconclusive
      NCT04523831 (Mahmud), 2020
              NCT04523831      		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
      		200/200 safety concern
      • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 93 % increase in clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 56 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
      • statistically significant 17.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
      Shahbaznejad, 2020
              IRCT20111224008507N3      		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
      		35/38 inconclusive

        COVID 19 outpatients meta-analysis

        ACTIV 6 ivermectin, 2022
                  NCT04885530        		 RCTivermectinplaceboCOVID 19 outpatientslow
        		817/774 inconclusive
          TOGETHER (ivermectine), 2022
                      NCT04727424          		 RCTivermectinplaceboCOVID 19 outpatientslow
          		679/679 inconclusive
          • inconclusive 10 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
          Lopez-Medina, 2021
                      NCT04405843          		 RCTivermectinplaceboCOVID 19 outpatientssome concern
          		200/200 inconclusive
          • inconclusive 7 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          IVERCORCOVID19 (Vallejos), 2020
                      NCT04529525          		 RCTivermectinplaceboCOVID 19 outpatientslow
          		250/251 inconclusive
          • inconclusive 35 % decrease in hospitalization (PE) with a high degree of certainty due to low risk of bias
          12 studies excluded by filtering options (8 RCT / 4 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons